What You Should Know:
– Citeline, a provider of intelligence solutions for the life sciences industry, today announced the launch of Protocol SmartDesign and Investigator SmartSelect, two new AI-powered tools designed to streamline and optimize clinical trial development.
– These innovative solutions are part of the Citeline SmartSolutions suite, which leverages the company’s extensive data assets to deliver actionable insights for life sciences organizations.
How Protocol SmartDesign Works
Protocol SmartDesign utilizes AI and machine learning to analyze vast amounts of data, including clinical trial data, real-world evidence, and patient demographics. This enables researchers to make informed decisions about protocol design, endpoint selection, and patient inclusion/exclusion criteria. By leveraging historical performance data, the tool can also help predict enrollment rates and trial duration.
Investigator SmartSelect streamlines the process of identifying and selecting qualified investigators for clinical trials. By combining AI with Citeline’s extensive investigator database, the tool can quickly generate a pool of potential sites and investigators based on specific protocol criteria. This significantly reduces the time and effort required for site selection, allowing researchers to focus on other critical aspects of trial design.
Both Protocol SmartDesign and Investigator SmartSelect are designed to reduce the likelihood of costly protocol amendments, which can significantly impact trial timelines and budgets. According to the Tufts Center for the Study of Drug Development, protocol amendments can add substantial costs to clinical trials. By optimizing protocol design and investigator selection, Citeline’s solutions help to mitigate this risk. “These solutions not only produce significant savings for medical, clinical operations and feasibility teams in terms of both time and cost, they ease the burden on study teams and site staff,” said Maureen Ladouceur, RN, president of Norstella, Citeline’s parent company. “As a clinician, this personally means a lot to me.”
